Daxor (DXR) Gets a Buy Rating from Maxim Group

In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Daxor (DXRResearch Report), with a price target of $22.00. The company’s shares closed last Tuesday at $10.58.

According to, Vendetti is a 4-star analyst with an average return of 4.9% and a 36.6% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, Applied DNA Sciences, and ReShape Lifesciences.

Daxor has an analyst consensus of Moderate Buy, with a price target consensus of $22.00.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $15.46 and a one-year low of $8.58. Currently, Daxor has an average volume of 2,359.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Daxor Corp. is a biotechnology company which develops and manufactures BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage; and andrology services, such as semen analysis, sperm washing and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in New York, NY.

Read More on DXR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed